Skip to main content
. 2001 Apr 15;7(2):243–247. doi: 10.3748/wjg.v7.i2.243

Table 2.

Currently conducted H. pylori-gastric cancer intervention trials with cancer endpoints

Name Country Target group Age group Sample size Main endpoints
SCISC China Population 30-65 2400 Gastric cancer
NCI China Population 35-69 3400 Gastric cancer , dysplasia
JITHP Japan Population 20-59 5000 Gastric cancer
BUPA U.K. Population 35-69 56000 Gastric cancer
PRISMA Germany Male subjects 55-65 3000 Gastric cancer
Austria with dysplasia,adenoma
Tchech Corpus
Republic dominant
gastritis
HHS Vulnerability Disclosure